Milestone Pharma (MIST) Q1 2026: 400+ Prescribers Signal Broad Cardamist Uptake in First Launch Quarter
Milestone Pharma’s inaugural commercial quarter for Cardamist revealed rapid prescriber adoption and early payer traction, providing a foundation for future growth. With 400+ unique prescribers and a key Express Scripts formulary win, the company’s launch strategy is resonating among cardiology providers. Attention now shifts to deepening coverage, expanding patient activation, and progressing the pivotal AFib-RVR trial.
Summary
- Prescriber Base Diversification: Early Cardamist adoption spans 400+ healthcare professionals, suggesting broad clinical buy-in.
- Payer Access Momentum: Express Scripts coverage accelerates commercial insurance reach and reduces access friction.
- Pipeline Execution: Rivera 301 Phase III AFib-RVR trial initiation positions MIST for multi-indication expansion.
Business Overview
Milestone Pharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cardiovascular therapies. Its lead product, Cardamist, is a rapid-acting, self-administered calcium channel blocker for acute episodes of paroxysmal supraventricular tachycardia (PSVT), a type of arrhythmia. The company generates revenue from Cardamist sales and is advancing Atripamil, the active ingredient, for atrial fibrillation with rapid ventricular rate (AFib-RVR) in a pivotal Phase III trial. Segments include commercial operations for Cardamist and clinical development for new indications.
Performance Analysis
Milestone’s first commercial quarter for Cardamist delivered approximately 600 prescriptions across 400+ unique prescribers, with month-over-month growth as promotional activity ramped. The initial sales, while modest in dollar terms, reflect early-stage launch dynamics and the need to build payer coverage and prescriber familiarity. Product revenues reached $0.2 million, supported by a measured approach to free drug programs and a focus on converting prescriptions through payer adjudication rather than sampling.
Operating cash burn was $23.7 million, reflecting elevated commercial expenses tied to launch investments, while R&D and G&A costs declined year-over-year as development activity shifted toward the Rivera 301 trial. The company’s cash position was fortified by a $75 million royalty purchase agreement and additional ATM and warrant proceeds, extending runway into the second half of 2027. Cardamist’s early script volume and payer wins provide a proof point for market need, while the broad prescriber base demonstrates traction beyond early adopters.
- Script Growth Trajectory: April prescriptions matched the combined February and March totals, indicating positive launch momentum.
- Prescriber Breadth: Over 400 unique HCPs wrote scripts, with cardiologists and electrophysiologists leading early adoption.
- Payer Coverage Expansion: Express Scripts formulary placement delivers access to 25% of commercially insured lives, with active negotiations ongoing for further expansion.
Milestone’s disciplined launch execution is building a foundation for deeper penetration as coverage and promotional frequency increase. The balance between commercial investment and capital preservation remains a key operational focus.
Executive Commentary
"It seems clear to us that the HCP audience we've engaged so far quickly understands the value that Cardamist brings to the patients with SVT due to its safety profile and ease of effective self-administration."
Joseph Oliveto, President and Chief Executive Officer
"In the landscape of commercial drug launches, getting a major PBM formulary placement within the first quarter of a launch is a significant achievement. We see this as clear validation of the clinical and economic value to payers."
Lorenz Muller, Chief Commercial Officer
Strategic Positioning
1. Broad Prescriber Engagement
Cardamist’s launch has attracted a wide spectrum of prescribers, with 50% of scripts from clinical cardiologists and 25% from electrophysiologists (EPs). This early diversity is strategic: EPs, as influential thought leaders, help drive awareness and guideline adoption, while clinical cardiologists represent the long-term volume opportunity as refills and repeat use increase. The company expects advanced practice providers (APPs) and eventually primary care to expand over time as comfort grows.
2. Accelerated Payer Access
Securing Express Scripts coverage within the first quarter is a rare achievement in specialty pharma launches. This unlocks access for approximately one in four commercially insured patients, reducing prior authorization burden and facilitating repeat fills. The company is leveraging this early win to negotiate with other major PBMs and Medicare plans, aiming to build a payer foundation that will support scaling promotional efforts and patient activation.
3. Commercial Investment Discipline
Milestone is intentionally calibrating its sales force and direct-to-patient (DTP) spend to align with coverage expansion. With a 60-rep team, the company is focusing on demonstrating demand without overwhelming prescribers with access friction. Pilots in non-personal promotion and targeted DTP are being tested for ROI, with broader investment to follow as coverage and prescriber awareness reach critical mass.
4. Pipeline Leverage and Clinical Execution
The Rivera 301 Phase III trial in AFib-RVR leverages the same self-administration model and operational infrastructure as the PSVT program. This approach maximizes operational efficiency and de-risks execution, while targeting a large, underserved patient population. The trial is designed for 150-200 events, with first patient enrollment expected in the second half of 2026, and readout anticipated in approximately two years.
Key Considerations
This quarter’s results reflect the early innings of a specialty pharma launch, with foundational signals for long-term adoption and growth. Execution across prescriber engagement, payer access, and commercial investment will determine the trajectory from here.
Key Considerations:
- Coverage Leverage: Express Scripts win is a springboard, but full commercial and Medicare coverage is necessary for broad adoption.
- Prescriber Depth vs. Breadth: Early breadth is strong, but deepening prescribing patterns and driving repeat use per patient will be critical metrics in coming quarters.
- Patient Activation Timing: DTP and patient marketing will be phased to avoid mismatched demand before sufficient HCP awareness and coverage.
- Capital Allocation: Cash runway into 2027 allows for measured scaling of commercial and clinical investments, but ongoing discipline is required as launch costs ramp.
Risks
Milestone faces execution risk in expanding payer coverage, particularly with Medicare and the remaining major PBMs, which will determine the addressable market size. Prescriber inertia, limited refill activity in the launch year, and potential for slower-than-expected patient uptake could dampen revenue ramp. Competitive responses, reimbursement headwinds, and trial enrollment for Rivera 301 are additional variables that could impact both commercial and pipeline progress.
Forward Outlook
For Q2 2026, Milestone expects:
- Continued sequential growth in Cardamist prescriptions as coverage and promotional frequency increase
- Further payer coverage wins and progress toward broader commercial and Medicare access
For full-year 2026, management maintained its outlook:
- Cash runway extends into H2 2027, supporting both Cardamist launch and Rivera 301 execution
Management highlighted focus areas:
- Driving disciplined commercial execution and expanding payer access
- Advancing Rivera 301 enrollment and leveraging launch learnings for pipeline expansion
Takeaways
Milestone’s disciplined, data-driven launch is delivering early traction, but the true test will be in scaling prescriber depth and payer access through 2026 and beyond.
- Launch Foundation Set: Early prescriber breadth and positive patient feedback validate Cardamist’s clinical value, but repeat use and broader coverage are the next hurdles.
- Payer Wins Are Pivotal: Express Scripts coverage is a milestone, but full commercial and Medicare access will define the addressable market and pace of adoption.
- Pipeline Execution Is Core to Upside: Rivera 301’s progression and successful leverage of the PSVT launch model could open a much larger AFib-RVR market.
Conclusion
Milestone Pharma’s first commercial quarter for Cardamist demonstrates strong early adoption signals and a disciplined approach to launch execution. Sustained momentum will depend on expanding payer coverage, deepening prescriber engagement, and executing on the AFib-RVR clinical program.
Industry Read-Through
Milestone’s rapid PBM access and prescriber breadth provide a template for specialty pharma launches, underscoring the importance of early payer wins and balanced commercial investment. The company’s approach to phased DTP and capital discipline is instructive for peers navigating first-in-class launches in underpenetrated markets. For cardiovascular innovators, the self-administered, rapid-acting model and focus on real-world prescriber and patient feedback highlight evolving expectations for specialty drug adoption and market access. The Rivera 301 trial, if successful, could signal broader opportunity for outpatient management of acute arrhythmias, reshaping treatment paradigms across the sector.